Biotech Values

[DewDiligence]

Scanning ABT’s 3Q09 PR, which just hit the wires, and the first place I looked was the sales line for Humira. (I’ll have more to say on the 3Q09 results later.)

http://finance.yahoo.com/news/Abbott-Reports-165-Percent-prnews-3645456301.html/print?x=0

Humira continues to be a monster: worldwide sales are running at an annualized rate of $6B and grew 32% year-over-year in constant currencies (24% in dollars).

$6B drugs growing at more than 30% do not come along every day and ABT says, “You ain’t seen nothing yet!”